Business Combination - Schedule Of Number Of Shares Of Common Stock Outstanding Immediately Following Consummation Of Busin (Details) - shares
|
Dec. 31, 2021 |
Dec. 31, 2020 |
| Business Acquisition [Line Items] |
|
|
| Common stock of MCAD |
23,602,718
|
11,146,510
|
| Total shares of Better Therapeutics Common Stock outstanding immediately following the business combination |
23,599,718
|
|
| PIPE Financing [Member] |
|
|
| Business Acquisition [Line Items] |
|
|
| Shares issued pursuant to the PIPE including transaction related shares |
5,098,750
|
|
| Business combination and PIPE financing shares |
8,424,990
|
|
| Mountain Crest Acquisition Corp I I [Member] |
|
|
| Business Acquisition [Line Items] |
|
|
| MCAD shares and rights outstanding prior to the business combination |
8,152,500
|
|
| Less: redemptions of MCAD shares prior to the business combination |
(4,826,260)
|
|
| Common stock of MCAD |
3,326,240
|
|
| Conversion of Legacy BTX SAFEs to Common Stock [Member] |
|
|
| Business Acquisition [Line Items] |
|
|
| Total shares of Better Therapeutics Common Stock outstanding immediately following the business combination |
4,080,481
|
|
| Conversion of Legacy BTX Preferred Seed A to Common Stock [Member] |
|
|
| Business Acquisition [Line Items] |
|
|
| Total shares of Better Therapeutics Common Stock outstanding immediately following the business combination |
1,010,696
|
|
| Conversion of Legacy BTX Preferred Series A to Common Stock [Member] |
|
|
| Business Acquisition [Line Items] |
|
|
| Total shares of Better Therapeutics Common Stock outstanding immediately following the business combination |
4,737,454
|
|
| Conversion of Legacy BTX Common Stock into New Common Stock [Member] |
|
|
| Business Acquisition [Line Items] |
|
|
| Total shares of Better Therapeutics Common Stock outstanding immediately following the business combination |
5,346,097
|
|